Cancer Chemotherapy and Skin Changes
Authors: NICHOLAS J. VOGELZANG
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 August 1985Cancer Chemotherapy and Skin ChangesNICHOLAS J. VOGELZANG, M.D., MARK J. RATAIN, M.D.NICHOLAS J. VOGELZANG, M.D., MARK J. RATAIN, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-2-303_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Lokich and Moore (1) have discussed the palmar-plantar erythrodysesthesia syndrome as it occurred in 18 patients, 17 of whom were receiving a continuous infusion of fluorouracil and 1 of whom was receiving doxorubicin. The syndrome consisted of symmetrical erythema, swelling, and tenderness of the hands and later the feet. After cessation of the infusion, desquamation of palms and soles occurred. Baer and colleagues (2) have stated that "identical skin toxocity" occurs in patients given high-dose cytoarabine. They have described the sequence of cytarabine-induced palmar-plantar skin toxicity as erythema, pain, and bullae formation followed by desquamation in 2...References1. LOKICHMOORE JC. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101:798-800. LinkGoogle Scholar2. BAERKINGWOLFF MLS. Palmar-plantar erythrodysesthesia and cytarabine [Letter]. Ann Intern Med. 1985;102:556. LinkGoogle Scholar3. DUFFY T. How much is too much high dose cytosine arabinoside? J Clin Oncol. 1985;3:601-3. CrossrefMedlineGoogle Scholar4. VOGELZANGRUANEDEMEESTER NMT. Phase I trial of an implanted battery-powered, programmable drug delivery system for continuous doxorubicin administration. J Clin Oncol. 1985;3:407-14. CrossrefMedlineGoogle Scholar5. FAINTUCKSHEPARDO'LAUGHLINBESCHORNERGAYNORLEVIN JKKJEB. Toxicity of continuous infusion 5-FU [Abstract]. Proc Am Soc Clin Oncol. 1985;4:92. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Chicago Chicago, IL 60637 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByTHE PROSPECTIVE OBSERVATIONAL STUDY ON CUTANEOUS ADVERSE DRUG REACTIONS TO CHEMOTHERAPYDrug ReactionsAn unusual presentation of hand-foot syndrome at the hidden area: The scrotum and penisPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centrePalmar-plantar erythrodysesthesiaCytotoxicity assessment of three therapeutic agents, cyclosporin-A, cisplatin and doxorubicin, with the ciliated protozoan Tetrahymena pyriformisIncidence and Severity of Hand–Foot Syndrome in Colorectal Cancer Patients Treated with Capecitabine: A Single-Institution ExperienceA phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcomaForewordA Case of Acral Erythema Induced by Methotrexate.Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapyThree Cases of Chemotherapy-induced Acral ErythemaPharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)Treatment of cytarabine acral erythema with corticosteroidsChemotherapy-induced acral erythemaErythema and swelling of ears after treatment with cytarabine for leukemiaPalmar-Plantar Skin Changes and CytarabineWIM G. PETERS, M.D., ROEL WILLEMZE, M.D. 1 August 1985Volume 103, Issue 2Page: 303-304KeywordsBlistersCancer chemotherapyDesquamationErythemaInflammationToxicity Issue Published: 1 August 1985 PDF DownloadLoading ...